Source: South China Morning PostThe Chinese drug maker Sinopharm has finally published the interim results from a Phase 3 trial of its Covid-19 vaccine after more than 200 million doses have been administered worldwide.The study, published in the Journal of the American Medical Association on Wednesday, has finally answered scientists’ calls for greater transparency, but the results do not cover some of the most vulnerable groups.Trial data shows a vaccine made by Sinopharm’s Beijing subsidiary, which has been approved by the…Read More